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Human papillomavirus type 32 (HPV32) is one of the etiological agents of a benign oral condition, focal epithelial
hyperplasia. However, the previously characterized properties of its E7 oncoprotein suggest a possible malignant nature for
this virus. In this study we characterized the properties of HPV32 E6 and E7. Our data show that HPV32 E7, despite its high
affinity for pRb, does not promote degradation of the cellular protein. In addition, HPV32 E6 does not prevent p53-mediated
apoptosis and/or cell cycle arrest. Moreover, coexpression of HPV32 E6 and E7 in primary human fibroblasts or keratino-
cytes does not alter their proliferative state. Together, these data provide evidence of the benign nature of HPV32. © 2002INTRODUCTION
The human papillomavirus (HPV) family comprises
over 100 different genotypes, which can be divided into
two subgroups, cutaneous and mucosal, according to
their tissue tropism (de Villiers, 1997; zur Hausen, 2000).
Both HPV groups are further separated into benign and
malignant types, based on the nature of the lesion in-
duced. The mucosal HPV16 is a high-risk, very common
type that has been detected in genital tract cancers as
well as in a subgroup of head and neck cancers (zur
Hausen, 2000). Two early proteins, E6 and E7, play a
major role in the transformation of host cells (Tomma-
sino, 2001). Key events in HPV-mediated transformation
are the inactivation of the tumor suppressors p53 and
pRb by E6 and E7, respectively, leading to deregulation of
fundamental cellular events, such as apoptosis and pro-
liferation (Tommasino, 2001).
Several studies have demonstrated that the efficiency
of E6 and E7 from different HPV types in inducing in vitro
cellular transformation strongly correlates with the in vivo
viral-induced events. For instance, the E6 and E7 of the
low-risk HPV types, which are mainly associated with
benign lesions, interact only weakly with the two tumor
suppressors and are not able to efficiently immortalize
primary human keratinocytes (Halbert et al., 1992;
Munger et al., 1989). In contrast, the high-risk HPV16 E6
and E7 are highly active in both events (Tommasino,
2001).
HPV13 and HPV32 are the etiological agents of a
1 To whom reprint requests should be addressed at Angewandtebenign oral condition termed focal epithelial hyperplasia
(FEH) (reviewed in Syrjanen and Syrjanen, 2000). This
type of lesion was initially found to be most prevalent in
the infant and juvenile population of restricted geograph-
ical areas (reviewed in Syrjanen and Syrjanen, 2000).
However, in the last 10 years this disease has been
reported more often in adults, particularly as an oppor-
tunistic infection in HIV patients (Marvan and Firth, 1998).
In a previous study we have observed that HPV32 and
HPV16 E7 proteins share several in vitro properties. Both
proteins bind pRb with approximately the same effi-
ciency and transform immortalized rodent fibroblasts,
which acquire the ability to grow in the absence of
mitogenic signals and in an anchorage-independent
manner (Caldeira et al., 2000). These molecular features
of HPV32 and the fact that FEH is increasing in adults
(e.g., HIV patients), who are frequently exposed to oral
carcinogens, raise the question of whether HPV32-in-
duced lesions may be a precondition for oral carcino-
genesis. To address this question we have characterized
in detail the biological properties of HPV32 E6 and E7 in
immortalized and primary cells. Our data indicate that
HPV32 does not represent a risk factor for tumor devel-
opment.
RESULTS
HPV32 E7 and pRb pathway inactivation
To determine the absolute binding affinity of HPV32 E7
protein to pRb, we performed a plate-binding assay as
previously described (Dong et al., 2001). Figure 1A and
Table 1 show that HPV32 E7 has a very high binding
affinity for pRb with a dissociation constant (Kcycle and apoptosis.
D) smaller
than the HPV16 E7 KD. These findings are in agreement
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with our previous data, which showed that HPV32 E7 is
more efficient than HPV16 E7 in binding pRb in the yeast
two-hybrid assay (Caldeira et al., 2000).
HPV16 E7 association with pRb leads to the rapid
degradation of the cellular protein via the proteasome
pathway (Tommasino, 2001). Therefore, we determined
whether HPV32 E7 is able to degrade pRb. We expressed
HPV16 and HPV32 E7 proteins in NIH3T3 cells using
retroviral vectors (pBabe). In order to detect the viral
proteins, the hemagglutinin tag (HA tag) was fused in
frame at the N-terminal of both E7s. Figure 1B shows that
both proteins were expressed in rodent cells. As ex-
pected, no pRb was detected in cells expressing HPV16
E7 (Fig. 1C). In contrast, HPV32 E7 cells have intracellu-
lar levels of pRb similar to the mock cells (Fig. 1C). Thus,
FIG. 1. HPV32 E7 does not efficiently inactivate the pRb pathway. (A) Ability of HPV32 E7 to associate with pRb in the plate binding assay. After
binding of pRb to the plate, purified T7-fused recombinant HPV16 E7 (closed circles), pRb binding deficient HPV16 E7 C24G mutant (triangles), and
HPV32 E7 (open circles) were added to the plate in increasing concentrations (0.7 nM–0.4 M). Bound T7-E7 was quantified as described (Dong et
al., 2001). The line shows the fit of the experimental data with a single rectangular hyperbola (Sigma plot) from which the E7 concentration to obtain
50% pRb binding (BC50%) and the KD were determined. The OD represents the normalized average of duplicate determinations. Bars represent SD.
(B) Expression of HA tag E7 proteins in NIH3T3 cells. One hundred micrograms of protein extract was fractionated on a 15% polyacrylamide–SDS gel,
transferred to PVDF membrane, and incubated with an anti-HA tag monoclonal antibody (MMS-101R, Babco, 1/1000). (C) HPV32 E7 does not induce
pRb degradation. One hundred micrograms of protein extracts of cells expressing the different viral proteins as indicated was applied to an 8%
polyacrylamide–SDS gel, transferred onto a PVDF membrane, and incubated with an anti-pRb (14001A; Pharmigen) or -tubulin (TUB2.1, Sigma)
antibody. The -tubulin signal was used as a loading control.
TABLE 1
Sequence of the pRb Binding Domain and Affinity
of Different E7 Proteins
HPV type pRb binding domain BC50 (nM) KD (M)
16 TTDLYCYEQLN 4.5 4.5  109
16 C24G TTDLYGYEQLN 8.9 8.9  108
32 PVDLYCYEQFD 2.4 2.4  109
Note. BC50 corresponds to binding concentration at 50% saturation
and the KD was calculated as described (Dong et al., 2001). Amino
acids in boldface indicate the core of the pRb binding domain. The
HPV16 E7 C24G harbors a mutation in the pRb binding site and has a
reduced affinity for the cellular protein.
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HPV32 E7, despite its high affinity for pRb, is not able to
promote its degradation. Similar results were obtained
with the E7 native proteins, thus excluding any possibility
of HA tag interference (data not shown).
HPV32 E7, G1/S progression, and CDK inhibitor
p16INK4a
We have recently reported that degradation of the
retinoblastoma protein by HPV16 E7 contributes to an
efficient abrogation of the cell cycle arrest imposed by
overexpression of p16INK4a (Giarre` et al., 2001). Since
HPV32 E7 does not degrade pRb, we asked whether its
strong binding to pRb might interfere with the pRb path-
way through other means. Therefore, we determined its
ability to promote G1/S progression in the presence of
high levels of p16INK4a. For this purpose, NIH3T3 cells
were double infected with recombinant retroviruses ex-
pressing the HPV16 or HPV32 E7 gene and p16INK4a as
previously described (Giarre` et al., 2001). Western blot
analysis revealed that p16INK4a was efficiently expressed
(Fig. 2A). In order to evaluate the ability of HPV32 E7 to
suppress the growth-inhibitory function of p16INK4a we
then determined the percentage of S phase cells in the
different cultures by flow cytometry. As shown in Fig. 2B,
HPV32 E7/p16INK4a cells showed a low level of prolifera-
tion, similarly to the cells expressing p16INK4a alone. This
is particularly evident after 7 days postinfection (Fig. 2B,
right). In contrast, HPV16 E7 was able to counteract the
inhibitory function of p16INK4a. Thus, HPV32 E7 does not
efficiently overcome the cell cycle arrest imposed by
high levels of p16INK4a.
HPV32 E6- and p53-mediated pathways
HPV16 E6 is able to bind and degrade p53, abrogating
the p53-mediated apoptotic and quiescent events (Man-
tovani and Banks, 2001). To determine whether HPV32
E6 has this property, we performed a GST pulldown
assay using GST/E6 bacterial recombinant protein and in
vitro translated human p53. Figure 3A shows that in
contrast to HPV16 E6, HPV32 E6 is unable to associate
FIG. 2. HPV 32 E7 does not efficiently neutralize the inhibitory activity of p16INK4a. (A) Expression of p16INK4a in NIH3T3 cells. One hundred micrograms
of protein extracts of cells infected with different recombinant retroviruses as indicated was applied to a 15% polyacrylamide–SDS gel, transferred
onto PVDF membrane, and incubated with antihuman p16INK4a antibody (kindly provided by Gordon Peters, Imperial Cancer Research Fund, London,
United Kingdom). (B) Percentage of cells coexpressing E7 proteins and p16INK4a in S phase. Cells were double infected with different recombinant
retroviruses as indicated, harvested 4 (left) or 7 (right) days postinfection with p16INK4a recombinant retrovirus, and stained with propidium iodide. The
cell cycle profile was analyzed by flow cytometry. The data represent the mean of three independent experiments. The bars represent the standard
deviations of the values obtained in independent experiments.
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FIG. 3. HPV32 E6 does not interfere with p53 functions. (A) HPV 32E6 does not bind p53 in a GST pulldown assay. Approximately 1 g of the different
E6 proteins N terminally fused to GST was immobilized on glutathione–Sepharose beads and incubated with in vitro translated and radiolabeled p53.
After 3 h, the beads were extensively washed, resuspended in SDS–sample buffer, and applied to a 10% polyacrylamide–SDS gel; 1/20 of the total
in vitro translated p53 used in the GST pulldown assay was also loaded on the gel (input). GST and GST16E7 were used as negative controls. (B)
The viral oncogenes are efficiently transcribed in primary oral fibroblasts. The cDNA was generated as described under Materials and Methods.
Primers used for PCR amplification flanked the ORFs (see Material and Methods). cDNA obtained from cells infected with empty pLXSN retrovirus
was probed with all the different primers and used as a control for the specificity of the amplified product. As an internal control, the GAPDH cDNA
was also amplified. The products were separated on 1% agarose gels and visualized by staining with ethidium bromide. (C) HPV32 E6 does not
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with p53. To further investigate the ability of HPV32 E6 to
interfere with p53 functions, we expressed the viral pro-
tein in primary human fibroblasts (POFs) and examined
its impact upon the p53 pathways. Expression of the viral
genes was confirmed by RT–PCR (Fig. 3B). Several stud-
ies have demonstrated that HPV16-infected cells, in ad-
dition to the full-length E6/E7 polycistronic mRNA, con-
tain different transcripts generated by alternative splicing
(termed E6*/E7) comprising truncated forms of the E6
gene fused to the full-length E7 gene (reviewed in Tom-
masino, 2001). Thus, the different bands detected in
HPV16 E6 expressing cells (Fig. 3B) are most likely due
to this event. Western blot analysis revealed that cells
expressing HPV32 E6 contained similar p53 levels to
mock cells, showing that this E6 protein does not target
p53 for degradation (Fig. 3C). In contrast, very low levels
of the tumor suppressor were detected in HPV16 E6 cells
(Fig. 3C). To determine whether p53 retains its biological
functions in the presence of HPV32 E6, we analyzed the
p53-mediated events in response to cellular stresses in
POFs expressing the viral gene. Actinomycin D is a DNA
intercalator and induces p53 accumulation, which in turn
triggers cell cycle arrest and/or apoptosis (Ljungman et
al., 1999). Actinomycin D treatment led to cell cycle arrest
in mock cells as well as in cells expressing HPV32 E6,
while HPV16 E6 POFs continued to proliferate (Fig. 3D).
The cell cycle arrest correlates with high levels of p53
and the cell cycle inhibitor p21cip1/waf1, a p53 transcrip-
tional target (data not shown). Similarly, HPV32 E6 was
not able to prevent apoptosis induced by actinomycin D
(Fig. 3E). Together, these data show that HPV32 E6 is not
able to alter the functions of p53.
Activities of HPV32 E6 and E7 in primary human cells
Our data show that HPV32 E6 or E7 alone does not
possess in vitro transforming activity. However, studies
on HPV16 have shown that the transforming activity of E7
is greatly increased in primary cells by the presence of
E6 (Halbert et al., 1991; Watanabe et al., 1989), reflecting
the natural situation in a viral infection. Therefore, we
next analyzed the events induced by coexpression of the
HPV32 E6 and E7 genes in primary human fibroblasts. To
determine whether the viral genes are expressed in
these cells, we performed RT–PCR analysis (Fig. 4A).
Similarly to the data presented in Fig. 3B, we detected
more than one transcript in cells expressing the HPV16
genes (Fig. 4A), while a single band was observed in the
case of HPV32. The fibroblasts expressing both HPV32
genes did not significantly differ in their growth from the
mock cells, while HPV16 E6/E7 cells were able to prolif-
erate faster (Fig. 4B). Moreover, we observed that after
approximately 70 days in culture, control (pLXSN) as well
as HPV32 E6/E7 fibroblasts presented the typical feature
of senescent cells, e.g., positive -galactosidase stain-
ing at pH 6.0 (Dimri et al., 1995) (data not shown). In
contrast, fibroblasts containing HPV16 E6 and E7 contin-
degrade p53 in POFs. One hundred micrograms of protein extracts of POFs expressing the different oncoproteins as indicated were separated on
a 10% polyacrylamide–SDS gel, transferred onto a PVDF membrane, and incubated with anti-p53 (Dako) or -tubulin (TUB2.1, Sigma) antibody. (D and
E) Induction of cell cycle arrest and apoptosis by DNA damaging agents in HPV32 E6 expressing cells. POFs were treated for 24 h with 2.5 g/ml
of actinomycin D and then harvested, fixed in 70% ethanol, and stained with propidium iodide. The percentage of the population in S phase (D) or
apoptosis (E) was determined by flow cytometry. The level of apoptosis is represented as the average of five independent experiments. The
percentage of apoptotic cells in the empty vector cell line (pLXSN) was taken as a standard (1) and all the other values were normalized accordingly.
The bottom panel shows a representative experiment. The apoptotic cells are visible under the bar.
FIG. 4. Coexpression of HPV32 E6 and E7 in human fibroblasts does
not alter their proliferative state. (A) Expression of the viral genes in
POFs. The expression of the viral genes was determined using RT–PCR
as described above. (B) Growth curves of POFs expressing the different
viral proteins. The growth of the different cell lines indicated in the
figure was monitored for more than 50 days. Cells were split at 80%
confluency. The doubling populations were calculated considering the
split ratio. Day 0 represents the first day after selection in neomycin.
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ued to proliferate without entering replicative senes-
cence. Next, we examined the effects of HPV32 E6 and
E7 expression in the natural host cells, oral primary
human keratinocytes. In two independent experiments
we observed that HPV16 E6 and E7 efficiently extended
the life span of the primary keratinocytes, while HPV32
E6/E7 were not able to do so (Table 2). Thus, our data
demonstrate that coexpression of HPV32 E6 and E7 does
not augment the activity of single proteins in altering
cellular proliferation.
DISCUSSION
In this study, we performed a detailed analysis of the
biological properties of HPV32 E6 and E7 in order to
evaluate the oncogenicity of this virus. We demonstrate
that HPV32 E7, despite its high affinity of binding to pRb,
is not able to induce its degradation. This feature is not
exclusive to HPV32 E7. For example, E7 from the cuta-
neous type HPV1, which is normally associated with
benign skin lesions, binds pRb with the same efficiency
as HPV16 E7 (Ciccolini et al., 1994) but does not promote
pRb degradation (Giarre` et al., 2001). We have previously
shown that pRb degradation by HPV16 E7 protein is
essential to overcome the G1 cell cycle arrest imposed
by the cyclin-dependent kinase inhibitor p16INK4a (Giarre`
et al., 2001). Consistent with this observation, HPV1 E7
has a very low efficiency in neutralizing the p16INK4a
inhibitory function (Giarre` et al., 2001). Here, we show
that HPV32 E7 behaves similarly to HPV1 E7, providing
further support for the link between E7-mediated pRb
degradation and deregulation of the G1/S transition. Like
HPV32 E7, HPV1 E7 displays transforming properties in
immortalized rodent fibroblasts, which do not express
p16INK4a (Schmitt et al., 1994). However, both E7s failed to
transform primary cells (Ciccolini et al., 1994; Schmitt et
al., 1994). Together, the results obtained with HPV1 E7
and HPV32 E7 indicate that pRb degradation represents
a key step in the inactivation of p16INK4a and suggest that
these activities are exclusive to oncogenic HPV types.
Unlike HPV16 E6, we have shown that HPV32 E6 does
not bind or degrade p53. Thus, the p53 tumor suppressor
activities are not altered in HPV32 E6 expressing cells.
Indeed, in these cells, when p53 is induced by cellular
stresses, it is still able to prompt apoptosis and arrest the
cell cycle. Histochemical analysis reveals that the most
prominent feature of FEH lesions is the presence of
atypical cells, termed FEH cells, easily identifiable by
their apoptotic features (Syrjanen and Syrjanen, 2000).
Taking these observations together, it is likely that in
vivo, during the course of the disease, the cellular de-
fense mechanism leads to eradication of HPV32-infected
cells by apoptosis without any resistance from HPV32
E6.
Our experiments in primary human cells provide an
additional explanation for the non-oncogenicity of the
virus. Coexpression of HPV32 E6 and E7 in primary
fibroblasts or keratinocytes does not alter the prolifera-
tive state of the host cells. Increased expression and/or
activity of p53, p21CIP1/WAF1, and p16INK4a are detected in
senescent cells (Bringold and Serrano, 2000), indicating
the importance of the integrity of the p53 and pRb path-
ways in this event. Since HPV32 E6 and E7 proteins are
not able to neutralize the tumor suppressors pRb and
p53, these are still able to exert their activities, driving
the cells into senescence, limiting their proliferative ca-
pacity, and preventing immortalization and transforma-
tion.
In summary, our data show that HPV32 is a benign
type and does not represent a risk in HPV-mediated
carcinogenesis.
MATERIALS AND METHODS
Plate binding assay
The assay was performed as described (Dong et al.,
2001). The E7 genes were cloned in frame and downstream
of the T7 tag sequence of the pET-21a expression vector
(Novagen/Calbiochem, Darmstadt, Germany). For produc-
tion of the GST-pRb fusion protein, part of the pRb gene
comprising the E7-interacting region (pocket domain,
amino acids 373–929) was cloned into the pGEX2T vector
(Amersham Pharmacia, Freiburg, Germany).
Retroviral expression vectors
The retroviral vectors pBabe-puro and pBabe-neo
have previously been described (Morgenstern and Land,
1990), while pLXSN was obtained from Clontech (Palo
Alto, California). The single open reading frames of
HPV16 and HPV32 E6 were cloned into pBabe-neo with
or without the HA tag sequence at the 5 end. HPV16
E6E7 and HPV32 E6E7 ORFs were cloned in pLXSN. The
pBabe-puro p16INK4a construct was kindly provided by
Bruno Amati (DNAX Research Institute, Palo Alto, Cali-
fornia).
Cell culture
NIH 3T3 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) and 4.5 g/liter of glucose, sup-
TABLE 2
Infection of Primary Human Oral Keratinocytes with Retroviruses
Expressing HPV16 E6/E7 and HPV32 E6/E7
Cell line I II
PLXSN (1 week)a (1 week)a
HPV16 E6/E7 Cultured for 8 months Cultured for 8 months
HPV32 E6/E7 (1 week)a (1 week)a
Note. I and II represent two independent infections. HPV16 E6/E7
keratinocytes were frozen at passage 22, 8 months after infection.
a The death of the culture.
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plemented with 10% calf serum (NIH 3T3). Bosc23, Phoe-
nix, and POFs were grown in DMEM supplemented with
10% fetal calf serum. Primary human oral keratinocytes
were grown in serum-free KGM medium supplemented
with epidermal growth factor (0.01 g/ml), insulin (5 g/
ml), hydrocortisone (0.4 g/ml), bovine pituitary extract (3
mg/100 ml), and gentamycin (all from Clonetics) on plas-
ticware previously coated with 1 ml/10 cm2 of coating
solution [fibronectin (10 g/ml), Sigma; BSA (1 mg/ml),
Roche; and collagen type I (30 g/ml), IBFB, Leipzig,
Germany].
Retroviral infections
High-titer retroviral supernatants (5  106 IU/ml)
were generated by transient transfection of Bosc23 cells
(ecotropic viruses) or Phoenix (amphotropic viruses) and
used to infect the cells as described previously (Pear et
al., 1993). After infection, NIH 3T3 cells were selected in
1 mg of G418/ml (7 to 8 days) or 2.0 g of puromycin/ml
(48 h). POFs were selected in 0.5 mg of G418 (6–7 days),
while primary oral keratinocytes were selected in 0.05
mg of G418/ml (2–3 days). Coexpression of the viral
genes and the cell cycle inhibitor p16INK4a was achieved
by consecutive retroviral infection as previously de-
scribed (Giarre` et al., 2001).
Determination of cellular parameters
Fluorescence-activated cell sorter (FACS) analysis
was performed as previously described (Giarre` et al.,
2001). For the detection of apoptosis (hypodiploid DNA
content), floating cells were also collected and pooled
together with the trypsinized cells. For determination of
apoptotic profile, the cells were left overnight at 4°C in
70% ethanol, stained with propidium iodide, and ana-
lyzed by FACS.
Immunoblot analysis and antibodies
Total cellular extracts were prepared in lysis buffer as
described (Giarre` et al., 2001). Cell extracts were frac-
tionated by electrophoresis on a SDS–polyacrylamide
gel. Immunoblot analysis was performed using the fol-
lowing antibodies: anti-HA tag (MMS-101R, Babco, Rich-
mond, California); anti-pRb (14001A; Pharmingen, San
Diego, California); anti--tubulin (clone TUB2.1, Sigma,
Deisenhofen, Germany); anti-p16INK4a (kindly provided by
Gordon Peters, Imperial Cancer Research Fund, London,
United Kingdom).
RT–PCR analysis
Total RNAwas extracted frommammalian cells using the
RNeasy kit (Qiagen GmbH, Germany) and adding a DNase
I treatment to prevent cellular DNA contamination in the
PCR reaction. cDNA was synthesized using the First Strand
cDNA Synthesis Kit (MBI Fermentas, Heidelberg, Germany)
using a random hexamer primer and M-MuLV reverse
transcriptase. The following primers were used to am-
plify the different viral cDNA by PCR: HPV16 E6, 5-
ATGTTTCAGGACCCACAG-3 (forward primer) and 5-
TTACAGCTGGGTTTCTCT-3 (reverse primer); HPV32 E6,
5-ATGGCAAGTACTTCTGCC-3 (forward primer) and 5-
TTCTCTGCACTGGGTAC-3 (reverse primer); HPV16 E6/
E7, 5-ATGTTTCAGGACCCACAG-3 (forward primer) and
5-TTATGGTTTCTGAGAACA-3 (reverse primer); HPV32
E6/E7, 5-ATGGCAAGTACTTCTGCC-3 (forward primer)
and 5-TCACTCCACGCAGGCACA-3 (reverse primer).
GST pulldown assay
Equal amounts of immobilized GST/recombinant pro-
teins were incubated with in vitro translated 35S-labeled
p53. After extensive washing steps, the amount of p53
bound to GST-HPV16 E6 was determined by electro-
phoresis and autoradiography.
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